Through a better understanding of the mechanisms and genetic predispositions to ADRs, we aim to improve the diagnosis, prognosis and clinical handling of such reactions and improve the benefit-risk ratio of medicines. This means that those who administer medicines will be better equipped to tailor treatments to their patients.
The work we conduct in order to harness crucial insights which ultimately leads to the reduction in ADR cases, includes:
- Development of novel preclinical test systems to identify toxicological potential of new drug candidates
- Development of novel clinical genotyping screens to identify susceptible individuals and inform their therapeutic management
- Informing the drug design process at an early stage to avoid incorporation of potentially toxic chemical motifs.